| Drug Name |
Cariprazine |
| Drug ID |
BADD_D00369 |
| Description |
Cariprazine is an antipsychotic drug developed by Gedeon Richter and marketed by Actavis under the trade name Vraylar. Cariprazine acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. This mechanism is relatively unique, since many other antipsychotics are D2 and 5-HT2A agonists. Cariprazine was approved by the FDA in September 2015 and is indicated in the treatment of schizophrenia and bipolar disorder. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder. |
| Indications and Usage |
Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I
disorder. |
| Marketing Status |
approved; investigational |
| ATC Code |
N05AX15 |
| DrugBank ID |
DB06016
|
| KEGG ID |
D09997
|
| MeSH ID |
C533287
|
| PubChem ID |
11154555
|
| TTD Drug ID |
D05XGO
|
| NDC Product Code |
61874-145; 61874-170; 70518-3157; 61874-161; 61874-116; 61874-131; 61874-115; 61874-160; 61874-146; 61874-130 |
| UNII |
F6RJL8B278
|
| Synonyms |
cariprazine | 3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea | Vraylar | cariprazine hydrochloride | N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-N,N-dimethylurea monohydrochloride | cariprazine HCl | trans-4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-N,N-dimethylcarbamoyl-cyclohexyl-amine hydrochloride | RGH-188 |
